Vutrisiran Sodium Suppliers & Bulk Manufacturers
Available Forms: injection (prefilled syringe)
Available Strengths: 25 mg/mL
Reference Brands: Amvuttra (USA)
Category:
Neurology
Vutrisiran Sodium is available in injection (prefilled syringe)
and strengths such as 25 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Vutrisiran Sodium is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Vutrisiran Sodium can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Vutrisiran, marketed under the brand name Amvuttra, is a targeted RNA interference (RNAi) therapeutic used for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis. It is a double-stranded small interfering RNA (siRNA) designed to specifically silence the transthyretin (TTR) gene in the liver, thereby reducing the production of both mutant and wild-type TTR protein. By lowering TTR levels, vutrisiran helps prevent the accumulation of misfolded amyloid deposits that damage peripheral nerves and the heart, the primary complications of hATTR amyloidosis.
Transthyretin is a serum protein responsible for transporting vitamin A and thyroxine. Mutations in the TTR gene cause amyloid fibril formation, leading to progressive polyneuropathy, autonomic dysfunction, and cardiomyopathy. If left untreated, the disease can be fatal within 5 to 10 years. Vutrisiran is administered via subcutaneous injection once every three months, providing sustained therapeutic effects while offering a convenient dosing schedule. With its mechanism directly addressing the underlying genetic cause of hATTR amyloidosis, vutrisiran represents a significant advancement in the management of this rare, progressive, and life-threatening disease.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing